Share Price and Basic Stock Data
Last Updated: November 28, 2025, 7:46 am
| PEG Ratio | -0.95 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bodal Chemicals Ltd operates in the Dyes & Pigments industry, currently trading at ₹54.2 with a market capitalization of ₹684 Cr. The company’s revenue has shown fluctuations over the reported periods, with sales standing at ₹1,574 Cr for FY 2023, down from ₹2,055 Cr in FY 2022. However, projections suggest an increase to ₹1,745 Cr in FY 2025 and a trailing twelve-month (TTM) revenue of ₹1,829 Cr. Quarterly sales have exhibited variability, peaking at ₹458.95 Cr in June 2022 before declining to ₹320.73 Cr in December 2022. The revenue trend indicates a recovery with sales rising to ₹393.59 Cr by March 2024 and further to ₹454.20 Cr by June 2025. This cyclic nature of revenue reflects the industry’s sensitivity to market demand and input cost fluctuations, which could affect future performance.
Profitability and Efficiency Metrics
The profitability metrics for Bodal Chemicals reveal mixed performance. The operating profit margin (OPM) stood at 10.48%, indicating a recovery from lower margins in previous quarters, such as 6.68% in June 2023. The net profit for FY 2023 recorded ₹38 Cr, a significant decline from ₹99 Cr in FY 2022. In terms of efficiency, the return on equity (ROE) was reported at 2.51%, while the return on capital employed (ROCE) was 5.51%. The interest coverage ratio (ICR) of 2.09x suggests that the company can comfortably cover its interest obligations, although it remains lower than previous years. The cash conversion cycle (CCC) of 125 days indicates a relatively longer period for converting investments into cash, which could impact liquidity. Overall, while profitability shows signs of improvement, efficiency metrics highlight areas requiring attention.
Balance Sheet Strength and Financial Ratios
Bodal Chemicals’ balance sheet reflects a total debt of ₹911 Cr against reserves of ₹1,080 Cr, indicating a debt-to-equity ratio of 0.81x. This level of debt could raise concerns about financial leverage and risk, particularly in a volatile market. The company reported a book value per share of ₹87.72, which, in conjunction with a price-to-book value (P/BV) ratio of 0.66x, suggests that the stock may be undervalued compared to its intrinsic worth. The current ratio stood at 1.17, indicating adequate liquidity to meet short-term obligations. However, the quick ratio of 0.73 suggests potential liquidity issues, as it excludes inventory from current assets. These financial ratios indicate a balance between growth potential and the risks associated with higher leverage.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bodal Chemicals indicates a strong promoter presence of 57%, which reflects confidence from the management in the company’s long-term prospects. Foreign institutional investors (FIIs) hold a minor stake of 0.29%, while domestic institutional investors (DIIs) have no significant holdings, which may suggest a lack of confidence from larger institutional players. The public holds 42.70% of the shares, with a total of 74,649 shareholders as of the latest report. This distribution of ownership could impact stock volatility, especially in times of market stress. The declining trend in FII participation, from 2.42% in December 2022 to the current level, could be a warning sign regarding investor sentiment. Maintaining investor confidence will be crucial for Bodal Chemicals as it navigates future challenges.
Outlook, Risks, and Final Insight
Bodal Chemicals faces a mixed outlook influenced by its operational performance and market dynamics. On one hand, the recovery in sales and improvement in operating margins present growth opportunities, especially with a TTM revenue of ₹1,829 Cr. However, risks include high debt levels, as indicated by a total debt-to-equity ratio of 0.81x, and the prolonged cash conversion cycle of 125 days, which may affect liquidity. Additionally, fluctuations in raw material costs and global demand for dyes and pigments pose external risks. The company must focus on improving operational efficiencies and managing debt to strengthen its financial position. If successful, Bodal Chemicals can leverage its market position for sustainable growth; otherwise, it may face challenges in an increasingly competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bodal Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dynamic Industries Ltd | 39.1 Cr. | 129 | 190/68.5 | 21.5 | 162 | 0.77 % | 5.68 % | 3.39 % | 10.0 |
| Daikaffil Chemicals India Ltd | 54.3 Cr. | 90.5 | 281/76.0 | 13.2 | 0.00 % | 18.6 % | 18.6 % | 10.0 | |
| Amal Ltd | 848 Cr. | 686 | 1,148/412 | 21.9 | 91.7 | 0.15 % | 36.3 % | 35.0 % | 10.0 |
| Vidhi Specialty Food Ingredients Ltd | 1,791 Cr. | 359 | 572/314 | 37.2 | 62.2 | 1.39 % | 18.7 % | 14.9 % | 1.00 |
| Ushanti Colour Chem Ltd | 52.8 Cr. | 47.0 | 67.1/38.0 | 37.7 | 0.00 % | 0.98 % | 5.98 % | 10.0 | |
| Industry Average | 1,388.08 Cr | 309.29 | 102.48 | 186.93 | 0.39% | 11.00% | 9.10% | 8.13 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 458.95 | 401.22 | 320.73 | 389.58 | 332.49 | 330.00 | 338.55 | 393.59 | 421.96 | 428.63 | 443.47 | 450.87 | 454.20 |
| Expenses | 409.12 | 369.13 | 296.18 | 362.67 | 310.28 | 306.51 | 314.68 | 368.48 | 387.50 | 395.97 | 398.97 | 403.61 | 406.59 |
| Operating Profit | 49.83 | 32.09 | 24.55 | 26.91 | 22.21 | 23.49 | 23.87 | 25.11 | 34.46 | 32.66 | 44.50 | 47.26 | 47.61 |
| OPM % | 10.86% | 8.00% | 7.65% | 6.91% | 6.68% | 7.12% | 7.05% | 6.38% | 8.17% | 7.62% | 10.03% | 10.48% | 10.48% |
| Other Income | 3.78 | 1.69 | 2.22 | 3.89 | 8.78 | 5.93 | 4.65 | 5.45 | 2.46 | 5.07 | 0.65 | 2.35 | 4.05 |
| Interest | 12.08 | 7.26 | 10.11 | 11.58 | 13.15 | 13.42 | 12.09 | 15.60 | 21.33 | 19.54 | 19.71 | 21.00 | 21.63 |
| Depreciation | 12.33 | 12.19 | 13.92 | 14.65 | 14.65 | 14.31 | 14.52 | 17.01 | 17.03 | 17.20 | 17.26 | 17.01 | 17.51 |
| Profit before tax | 29.20 | 14.33 | 2.74 | 4.57 | 3.19 | 1.69 | 1.91 | -2.05 | -1.44 | 0.99 | 8.18 | 11.60 | 12.52 |
| Tax % | 22.84% | 28.33% | 11.31% | 38.51% | 30.72% | 26.04% | 49.21% | -200.00% | -18.75% | 124.24% | 33.74% | -25.09% | 23.88% |
| Net Profit | 22.53 | 10.27 | 2.43 | 2.81 | 2.21 | 1.24 | 0.98 | 2.04 | -1.18 | -0.24 | 5.42 | 14.50 | 9.53 |
| EPS in Rs | 1.95 | 0.84 | 0.19 | 0.22 | 0.18 | 0.10 | 0.08 | 0.16 | -0.09 | -0.02 | 0.43 | 1.15 | 0.76 |
Last Updated: August 20, 2025, 12:40 pm
Below is a detailed analysis of the quarterly data for Bodal Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 454.20 Cr.. The value appears strong and on an upward trend. It has increased from 450.87 Cr. (Mar 2025) to 454.20 Cr., marking an increase of 3.33 Cr..
- For Expenses, as of Jun 2025, the value is 406.59 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 403.61 Cr. (Mar 2025) to 406.59 Cr., marking an increase of 2.98 Cr..
- For Operating Profit, as of Jun 2025, the value is 47.61 Cr.. The value appears strong and on an upward trend. It has increased from 47.26 Cr. (Mar 2025) to 47.61 Cr., marking an increase of 0.35 Cr..
- For OPM %, as of Jun 2025, the value is 10.48%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.48%.
- For Other Income, as of Jun 2025, the value is 4.05 Cr.. The value appears strong and on an upward trend. It has increased from 2.35 Cr. (Mar 2025) to 4.05 Cr., marking an increase of 1.70 Cr..
- For Interest, as of Jun 2025, the value is 21.63 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Mar 2025) to 21.63 Cr., marking an increase of 0.63 Cr..
- For Depreciation, as of Jun 2025, the value is 17.51 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.01 Cr. (Mar 2025) to 17.51 Cr., marking an increase of 0.50 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.52 Cr.. The value appears strong and on an upward trend. It has increased from 11.60 Cr. (Mar 2025) to 12.52 Cr., marking an increase of 0.92 Cr..
- For Tax %, as of Jun 2025, the value is 23.88%. The value appears to be increasing, which may not be favorable. It has increased from -25.09% (Mar 2025) to 23.88%, marking an increase of 48.97%.
- For Net Profit, as of Jun 2025, the value is 9.53 Cr.. The value appears to be declining and may need further review. It has decreased from 14.50 Cr. (Mar 2025) to 9.53 Cr., marking a decrease of 4.97 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.76. The value appears to be declining and may need further review. It has decreased from 1.15 (Mar 2025) to 0.76, marking a decrease of 0.39.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 960 | 1,043 | 908 | 1,233 | 1,142 | 1,424 | 1,375 | 1,226 | 2,055 | 1,574 | 1,395 | 1,745 | 1,829 |
| Expenses | 770 | 859 | 758 | 1,007 | 946 | 1,187 | 1,237 | 1,140 | 1,835 | 1,441 | 1,284 | 1,578 | 1,667 |
| Operating Profit | 189 | 184 | 150 | 226 | 196 | 236 | 138 | 87 | 220 | 133 | 111 | 167 | 162 |
| OPM % | 20% | 18% | 16% | 18% | 17% | 17% | 10% | 7% | 11% | 8% | 8% | 10% | 9% |
| Other Income | -70 | 5 | 19 | 15 | 8 | 13 | 10 | 16 | -2 | 12 | 9 | 2 | 27 |
| Interest | 47 | 27 | 12 | 9 | 5 | 9 | 19 | 17 | 29 | 41 | 54 | 82 | 82 |
| Depreciation | 25 | 22 | 26 | 29 | 12 | 21 | 28 | 30 | 47 | 53 | 60 | 69 | 69 |
| Profit before tax | 47 | 139 | 131 | 204 | 186 | 219 | 101 | 55 | 142 | 51 | 5 | 19 | 38 |
| Tax % | 35% | 34% | 34% | 35% | 33% | 35% | 15% | 28% | 31% | 25% | -37% | 4% | |
| Net Profit | 30 | 92 | 86 | 133 | 122 | 141 | 86 | 40 | 99 | 38 | 6 | 18 | 35 |
| EPS in Rs | 2.76 | 8.41 | 7.88 | 12.18 | 10.03 | 11.72 | 7.12 | 3.43 | 8.51 | 3.03 | 0.51 | 1.47 | 2.82 |
| Dividend Payout % | 0% | 0% | 8% | 7% | 8% | 7% | 11% | 23% | 9% | 3% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 206.67% | -6.52% | 54.65% | -8.27% | 15.57% | -39.01% | -53.49% | 147.50% | -61.62% | -84.21% | 200.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -213.19% | 61.17% | -62.92% | 23.84% | -54.58% | -14.48% | 200.99% | -209.12% | -22.59% | 284.21% |
Bodal Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | -5% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -14% |
| 5 Years: | -26% |
| 3 Years: | -45% |
| TTM: | 875% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -2% |
| 3 Years: | -13% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 4% |
| 3 Years: | 2% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:10 am
Balance Sheet
Last Updated: September 10, 2025, 1:35 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 24 | 24 | 24 | 24 | 24 | 25 | 25 | 25 |
| Reserves | 43 | 135 | 213 | 341 | 673 | 805 | 907 | 957 | 1,028 | 1,053 | 1,057 | 1,080 |
| Borrowings | 397 | 234 | 143 | 151 | 181 | 171 | 257 | 454 | 676 | 760 | 904 | 911 |
| Other Liabilities | 131 | 144 | 132 | 193 | 194 | 290 | 267 | 314 | 385 | 283 | 294 | 324 |
| Total Liabilities | 593 | 534 | 510 | 707 | 1,072 | 1,290 | 1,455 | 1,749 | 2,113 | 2,120 | 2,281 | 2,339 |
| Fixed Assets | 168 | 190 | 192 | 222 | 437 | 609 | 656 | 804 | 817 | 967 | 1,314 | 1,301 |
| CWIP | 9 | 3 | 0 | 9 | 19 | 26 | 7 | 14 | 70 | 193 | 68 | 61 |
| Investments | 1 | 2 | 2 | 17 | 17 | 6 | 3 | 6 | 0 | 0 | 13 | 0 |
| Other Assets | 415 | 339 | 316 | 459 | 599 | 650 | 789 | 924 | 1,227 | 960 | 886 | 977 |
| Total Assets | 593 | 534 | 510 | 707 | 1,072 | 1,290 | 1,455 | 1,749 | 2,113 | 2,120 | 2,281 | 2,339 |
Below is a detailed analysis of the balance sheet data for Bodal Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,080.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,057.00 Cr. (Mar 2024) to 1,080.00 Cr., marking an increase of 23.00 Cr..
- For Borrowings, as of Mar 2025, the value is 911.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 904.00 Cr. (Mar 2024) to 911.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 324.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 294.00 Cr. (Mar 2024) to 324.00 Cr., marking an increase of 30.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,339.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,281.00 Cr. (Mar 2024) to 2,339.00 Cr., marking an increase of 58.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,301.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,314.00 Cr. (Mar 2024) to 1,301.00 Cr., marking a decrease of 13.00 Cr..
- For CWIP, as of Mar 2025, the value is 61.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2024) to 61.00 Cr., marking a decrease of 7.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 13.00 Cr..
- For Other Assets, as of Mar 2025, the value is 977.00 Cr.. The value appears strong and on an upward trend. It has increased from 886.00 Cr. (Mar 2024) to 977.00 Cr., marking an increase of 91.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,339.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,281.00 Cr. (Mar 2024) to 2,339.00 Cr., marking an increase of 58.00 Cr..
Notably, the Reserves (1,080.00 Cr.) exceed the Borrowings (911.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -208.00 | -50.00 | 7.00 | 75.00 | 15.00 | 65.00 | -119.00 | -367.00 | -456.00 | -627.00 | -793.00 | -744.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 69 | 67 | 56 | 91 | 85 | 121 | 139 | 105 | 97 | 100 | 83 |
| Inventory Days | 72 | 43 | 57 | 60 | 59 | 86 | 91 | 141 | 141 | 119 | 139 | 139 |
| Days Payable | 66 | 62 | 67 | 73 | 79 | 91 | 87 | 102 | 81 | 72 | 102 | 97 |
| Cash Conversion Cycle | 92 | 50 | 58 | 43 | 71 | 79 | 124 | 178 | 165 | 144 | 137 | 125 |
| Working Capital Days | 41 | 23 | 18 | 21 | 58 | 50 | 65 | 73 | 55 | 49 | 19 | 20 |
| ROCE % | 39% | 39% | 35% | 46% | 27% | 24% | 11% | 5% | 12% | 5% | 3% | 6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.25 |
| Diluted EPS (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.24 |
| Cash EPS (Rs.) | 6.91 | 5.32 | 7.25 | 11.86 | 5.74 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 87.72 | 86.04 | 85.79 | 85.92 | 80.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 87.72 | 86.04 | 85.79 | 85.92 | 80.10 |
| Revenue From Operations / Share (Rs.) | 138.55 | 110.87 | 125.32 | 167.42 | 100.26 |
| PBDIT / Share (Rs.) | 13.55 | 9.50 | 11.54 | 19.34 | 8.38 |
| PBIT / Share (Rs.) | 8.11 | 4.69 | 7.31 | 15.54 | 5.89 |
| PBT / Share (Rs.) | 1.53 | 0.37 | 4.05 | 11.60 | 4.53 |
| Net Profit / Share (Rs.) | 1.47 | 0.51 | 3.03 | 8.06 | 3.25 |
| NP After MI And SOA / Share (Rs.) | 1.47 | 0.51 | 3.03 | 8.79 | 3.43 |
| PBDIT Margin (%) | 9.77 | 8.56 | 9.20 | 11.55 | 8.35 |
| PBIT Margin (%) | 5.85 | 4.22 | 5.83 | 9.28 | 5.87 |
| PBT Margin (%) | 1.10 | 0.33 | 3.22 | 6.92 | 4.51 |
| Net Profit Margin (%) | 1.06 | 0.46 | 2.41 | 4.81 | 3.24 |
| NP After MI And SOA Margin (%) | 1.06 | 0.46 | 2.41 | 5.25 | 3.42 |
| Return on Networth / Equity (%) | 1.67 | 0.59 | 3.52 | 10.19 | 4.30 |
| Return on Capital Employeed (%) | 6.43 | 3.70 | 6.12 | 14.44 | 6.33 |
| Return On Assets (%) | 0.78 | 0.28 | 1.79 | 5.07 | 2.40 |
| Long Term Debt / Equity (X) | 0.36 | 0.40 | 0.33 | 0.20 | 0.10 |
| Total Debt / Equity (X) | 0.81 | 0.82 | 0.70 | 0.54 | 0.35 |
| Asset Turnover Ratio (%) | 0.75 | 0.63 | 0.74 | 0.96 | 0.71 |
| Current Ratio (X) | 1.17 | 1.17 | 1.37 | 1.41 | 1.43 |
| Quick Ratio (X) | 0.73 | 0.78 | 0.89 | 0.85 | 0.92 |
| Inventory Turnover Ratio (X) | 5.77 | 4.98 | 2.24 | 3.10 | 3.25 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 19.44 | 25.79 | 9.10 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 1.87 | 10.76 | 6.35 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 80.56 | 74.21 | 90.90 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 98.13 | 89.24 | 93.65 | 0.00 |
| Interest Coverage Ratio (X) | 2.09 | 2.20 | 3.53 | 8.04 | 6.16 |
| Interest Coverage Ratio (Post Tax) (X) | 1.24 | 1.12 | 1.93 | 4.98 | 3.39 |
| Enterprise Value (Cr.) | 1607.20 | 1786.11 | 1466.28 | 1791.70 | 1436.56 |
| EV / Net Operating Revenue (X) | 0.92 | 1.28 | 0.93 | 0.87 | 1.17 |
| EV / EBITDA (X) | 9.42 | 14.95 | 10.12 | 7.56 | 14.01 |
| MarketCap / Net Operating Revenue (X) | 0.42 | 0.66 | 0.46 | 0.60 | 0.89 |
| Retention Ratios (%) | 0.00 | 80.55 | 74.20 | 90.89 | 0.00 |
| Price / BV (X) | 0.66 | 0.85 | 0.67 | 1.17 | 1.13 |
| Price / Net Operating Revenue (X) | 0.42 | 0.66 | 0.46 | 0.60 | 0.89 |
| EarningsYield | 0.02 | 0.01 | 0.05 | 0.08 | 0.03 |
After reviewing the key financial ratios for Bodal Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 5. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 5. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For Cash EPS (Rs.), as of Mar 25, the value is 6.91. This value is within the healthy range. It has increased from 5.32 (Mar 24) to 6.91, marking an increase of 1.59.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 87.72. It has increased from 86.04 (Mar 24) to 87.72, marking an increase of 1.68.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 87.72. It has increased from 86.04 (Mar 24) to 87.72, marking an increase of 1.68.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 138.55. It has increased from 110.87 (Mar 24) to 138.55, marking an increase of 27.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.55. This value is within the healthy range. It has increased from 9.50 (Mar 24) to 13.55, marking an increase of 4.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.11. This value is within the healthy range. It has increased from 4.69 (Mar 24) to 8.11, marking an increase of 3.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.37 (Mar 24) to 1.53, marking an increase of 1.16.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 2. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 2. It has increased from 0.51 (Mar 24) to 1.47, marking an increase of 0.96.
- For PBDIT Margin (%), as of Mar 25, the value is 9.77. This value is below the healthy minimum of 10. It has increased from 8.56 (Mar 24) to 9.77, marking an increase of 1.21.
- For PBIT Margin (%), as of Mar 25, the value is 5.85. This value is below the healthy minimum of 10. It has increased from 4.22 (Mar 24) to 5.85, marking an increase of 1.63.
- For PBT Margin (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 10. It has increased from 0.33 (Mar 24) to 1.10, marking an increase of 0.77.
- For Net Profit Margin (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 5. It has increased from 0.46 (Mar 24) to 1.06, marking an increase of 0.60.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 8. It has increased from 0.46 (Mar 24) to 1.06, marking an increase of 0.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.67. This value is below the healthy minimum of 15. It has increased from 0.59 (Mar 24) to 1.67, marking an increase of 1.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.43. This value is below the healthy minimum of 10. It has increased from 3.70 (Mar 24) to 6.43, marking an increase of 2.73.
- For Return On Assets (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has increased from 0.28 (Mar 24) to 0.78, marking an increase of 0.50.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.36. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.36, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.81. This value is within the healthy range. It has decreased from 0.82 (Mar 24) to 0.81, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.63 (Mar 24) to 0.75, marking an increase of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 1.17.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.73, marking a decrease of 0.05.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.77. This value is within the healthy range. It has increased from 4.98 (Mar 24) to 5.77, marking an increase of 0.79.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 19.44 (Mar 24) to 0.00, marking a decrease of 19.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.87 (Mar 24) to 0.00, marking a decrease of 1.87.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 80.56 (Mar 24) to 0.00, marking a decrease of 80.56.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.13 (Mar 24) to 0.00, marking a decrease of 98.13.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 3. It has decreased from 2.20 (Mar 24) to 2.09, marking a decrease of 0.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 3. It has increased from 1.12 (Mar 24) to 1.24, marking an increase of 0.12.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,607.20. It has decreased from 1,786.11 (Mar 24) to 1,607.20, marking a decrease of 178.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.28 (Mar 24) to 0.92, marking a decrease of 0.36.
- For EV / EBITDA (X), as of Mar 25, the value is 9.42. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 9.42, marking a decrease of 5.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 1. It has decreased from 0.66 (Mar 24) to 0.42, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 80.55 (Mar 24) to 0.00, marking a decrease of 80.55.
- For Price / BV (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.66, marking a decrease of 0.19.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 1. It has decreased from 0.66 (Mar 24) to 0.42, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bodal Chemicals Ltd:
- Net Profit Margin: 1.06%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.43% (Industry Average ROCE: 11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.67% (Industry Average ROE: 9.1%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.8 (Industry average Stock P/E: 102.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.81
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.06%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Dyes & Pigments | Bodal Corporate House, Beside Maple Green Residency, Ahmedabad Gujarat 380059 | info@bodal.com http://www.bodal.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suresh J Patel | Chairman & Managing Director |
| Mr. Bhavin S Patel | Executive Director |
| Mr. Ankit S Patel | Executive Director |
| Mr. Rohit Maloo | Independent Director |
| Mr. Nalin Kumar | Independent Director |
| Mrs. Neha Huddar | Independent Director |
| Mr. Mayank K Mehta | Independent Director |
| Mr. Rajarshi Gosh | Director |
FAQ
What is the intrinsic value of Bodal Chemicals Ltd?
Bodal Chemicals Ltd's intrinsic value (as of 03 December 2025) is 34.31 which is 36.70% lower the current market price of 54.20, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 684 Cr. market cap, FY2025-2026 high/low of 81.5/49.6, reserves of ₹1,080 Cr, and liabilities of 2,339 Cr.
What is the Market Cap of Bodal Chemicals Ltd?
The Market Cap of Bodal Chemicals Ltd is 684 Cr..
What is the current Stock Price of Bodal Chemicals Ltd as on 03 December 2025?
The current stock price of Bodal Chemicals Ltd as on 03 December 2025 is 54.2.
What is the High / Low of Bodal Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bodal Chemicals Ltd stocks is 81.5/49.6.
What is the Stock P/E of Bodal Chemicals Ltd?
The Stock P/E of Bodal Chemicals Ltd is 18.8.
What is the Book Value of Bodal Chemicals Ltd?
The Book Value of Bodal Chemicals Ltd is 89.1.
What is the Dividend Yield of Bodal Chemicals Ltd?
The Dividend Yield of Bodal Chemicals Ltd is 0.00 %.
What is the ROCE of Bodal Chemicals Ltd?
The ROCE of Bodal Chemicals Ltd is 5.51 %.
What is the ROE of Bodal Chemicals Ltd?
The ROE of Bodal Chemicals Ltd is 2.51 %.
What is the Face Value of Bodal Chemicals Ltd?
The Face Value of Bodal Chemicals Ltd is 2.00.